Microwave-Enhanced Friedländer Synthesis for the Rapid Assembly of Halogenated Quinolines with Antibacterial and Biofilm Eradication Activities against Drug Resistant and Tolerant Bacteria


†Department of Medicinal Chemistry, ‡Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida, Gainesville, Florida 32610, United States

*Corresponding Author: rhuigens@cop.ufl.edu

Supporting Information

1.) General Information  S2
2.) Synthetic Procedures with Tabulated Characterization Data  S3
3.) Biological Methods  S14
4.) Literature References  S16
5.) Supporting Images of Biological Experiments  S17
6.) ¹H NMR & ¹³C NMR Spectra  S21
1.) General Information:

All synthetic reactions were carried out under an inert atmosphere of argon unless otherwise specified. Reagents and commercially available biological controls (i.e., antibiotics) were purchased at ≥ 95% purity and used without further purification. All microwave reactions were carried out in sealed tubes in an Anton Paar Monowave 300 Microwave Synthesis Reactor. A constant power was applied to ensure reproducibility. Temperature control was automated via IR sensor and all indicated temperatures correspond to the maximal temperature reached during each experiment. Analytical thin layer chromatography (TLC) was performed using 250 μm Silica Gel 60 F254 pre-coated plates (EMD Chemicals Inc.). Flash column chromatography was performed using 230-400 Mesh 60Å Silica Gel from Sorbent Technologies. All melting points were obtained, uncorrected, using a Mel-Temp capillary melting point apparatus from Laboratory Services, Inc.

NMR experiments were recorded using broadband probes on a Varian Mercury-Plus-400 spectrometer via VNMR-J software (400 MHz for 1H and 100 MHz for 13C). All spectra are presented using MestReNova 8.1 (Mnova) software and are displayed without the use of the signal suppression function. Spectra were obtained in the following solvents (reference peaks also included for 1H and 13C NMRs): CDCl₃ (1H NMR: 7.26 ppm; 13C NMR: 77.23 ppm), CD₃OD (1H NMR: 3.31 ppm; 13C NMR: 49.00 ppm), and d₆-DMSO (1H NMR: 2.50 ppm; 13C NMR: 39.52 ppm). All NMR experiments were performed at room temperature. Chemical shift values (δ) are reported in parts per million (ppm) for all 1H NMR and 13C NMR spectra. 1H NMR multiplicities are reported as: s = singlet, br. s = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet. High-resolution mass spectra were obtained for new compounds from the Mass Spectrometry Facility in the Chemistry Department at the University of Florida.

Bacterial strains used during these investigations include: methicillin-resistant Staphylococcus aureus (Clinical Isolate from Shands Hospital in Gainesville, FL: MRSA-2; ATCC strains: BAA 1707, BAA 44) methicillin-resistant Staphylococcus epidermidis (MRSE strain ATCC 35984), and vancomycin-resistant Enterococcus faecium (VRE strain ATCC 700221). All compounds were stored as DMSO stocks at room temperature in the absence of light for several months at a time without observing any loss in biological activity. To ensure compound integrity of our DMSO stock solutions, we did not subject DMSO stocks of our test compounds to freeze-thaw cycles.

This work was supported by the Emerging Pathogens Institute and the College of Pharmacy at the University of Florida.
2. Synthetic Procedures with Tabulated Characterization Data:

3-Hydroxy-2-nitrobenzaldehyde (22). To a stirring solution of 3-hydroxybenzaldehyde 21 (618 mg, 5.0 mmol) in dichloromethane (10 mL) was added tetrabutylammoniumhydrogen sulfate (85.0 mg, 0.25 mmol) and isopropyl nitrate (1.27 mL, 12.5 mmol). Concentrated sulfuric acid (610 µL) was added dropwise and the resulting reaction mixture was allowed to stir at room temperature for 15 minutes. The reaction contents were then transferred to a separatory funnel containing 50 mL of an aqueous saturated sodium bicarbonate solution. Dichloromethane was then used to extract the crude product. The combined organic layers were dried with anhydrous sodium sulfate, filtered and concentrated in vacuo. The resulting solid was adsorbed onto silica gel and purified via flash column chromatography eluting with 99:1 to 4:1 hexanes:ethyl acetate to give isomer 23 ($R_f = 0.44$ in 3:1 hexanes:ethyl acetate) as a yellow solid (201 mg, 24% yield) followed by the desired product 22 ($R_f = 0.19$ in 3:1 hexanes:ethyl acetate) as a pale yellow solid (411 mg, 47% yield). Note: We have previously reported this procedure. We were able to obtain 22 (CAS number: 42123-33-1) in 64% yield (2.18 g) during the course of these investigations.

Synthesis of 2-amino-3-hydroxybenzaldehyde (20). Iron powder (895 mg, 16 mmol) was added to a stirring solution of 3-hydroxy-2-nitrobenzaldehyde 22 (268 mg, 1.60 mmol) dissolved in 4:1 mixture of ethanol:water (6 mL). Concentrated hydrochloric acid (14 µL, 0.16 mmol) was added to the reaction mixture which was heated to reflux for 5 hours until complete (determined by TLC analysis). After the completion of the reaction, the reaction was cooled and the resulting suspension was passed through a short plug of celite eluting with ethanol. The resulting solution was concentrated in vacuo to afford pure 20 (1.49 g, 84% yield). Note: We have previously reported this procedure.

Method A Friedländer synthesis of 8-hydroxyquinolines (1a – 6a, 10a). To a sealed microwave vial was added 2-amino-3-hydroxybenzaldehyde 20 (47.6 mg, 0.35 mmol), potassium hydroxide (43.0 mg, 0.76 mmol) and 3-pentanone 25 (56 µL, 0.52 mmol). The resulting mixture was then heated to 130 °C in the microwave
reactor for 40 minutes. After that time, the reaction was then allowed to cool and the solvent was removed in vacuo. The crude residue was taken up in dichloromethane, transferred to a separatory funnel and then neutralized with 2N hydrochloric acid. The solution was then extracted with dichloromethane three times. The organic layers were combined, dried with anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude solid was purified via flash column chromatography eluting with 95:5 to 4:1 hexanes:ethyl acetate to afford quinoline 10a as a white solid (61.4 mg, 95%).

Yield: 84% yield; 27.1 mg of 1a was isolated as a white solid.

Note: We have previously reported a synthesis of this compound, without microwave assistance.1

Yield: 76% yield; 63.9 mg of 2a was isolated as a white solid.

1H NMR (400 MHz, CDCl3): δ 8.44 – 8.33 (br. s, 1H), 8.22 (d, J = 8.6 Hz, 1H), 8.19 – 8.14 (m, 2H), 7.92 (d, J = 8.6 Hz, 1H), 7.59 – 7.40 (m, 3H), 7.35 (dd, J = 8.3, 1.3 Hz, 1H), 7.21 (dd, J = 7.5, 1.3 Hz, 1H).

MP: 45 - 47 °C, lit. 55 °C.

Note: 1H NMR spectrum and melting point match previously reported values.3

Yield: 83% yield; 57.1 mg of 3a was isolated as a white solid.

1H NMR (400 MHz, CDCl3): δ 8.77 – 8.68 (m, 1H), 8.59 (d, J = 8.6 Hz, 1H), 8.56 (dt, J = 8.0, 1.1 Hz, 1H), 8.35 (br. s, 1H), 8.26 (d, J = 8.6 Hz, 1H), 7.85 (td, J = 7.8, 1.8 Hz, 1H), 7.46 (dd, J = 7.9, 7.9 Hz, 1H), 7.39 – 7.32 (m, 2H), 7.20 (dd, J = 7.6, 1.3 Hz, 1H).

13C NMR (100 MHz, CDCl3): δ 155.5, 153.8, 152.3, 149.2, 137.6, 137.0, 136.9, 128.5, 128.0, 124.2, 121.5, 119.7, 117.9, 110.2.

MP: 121 - 123 °C, lit. 119 - 121 °C.

Note: NMR spectra and melting point match previously reported values.4

Yield: 52% yield; 40.0 mg of 4a was isolated as a white solid.

1H NMR (400 MHz, CDCl3): δ 8.63 (d, J = 2.0 Hz, 1H), 7.90 (d, J = 2.0 Hz, 1H), 7.42 (dd, J = 8.3, 7.6 Hz, 1H), 7.25 (dd, J = 8.3, 1.2 Hz, 1H), 7.12 (dd, J = 7.6, 1.2 Hz, 1H), 2.51 (s, 3H).

13C NMR (100 MHz, CDCl3): δ 152.4, 150.0, 136.9, 135.0, 131.5, 128.6, 128.0, 117.5, 109.5, 19.0.

Note: NMR spectra match previously reported values.5

Yield: 48% yield; 48.6 mg of 5a was isolated as a white solid.

1H NMR (400 MHz, CDCl3): δ 8.66 (d, J = 2.1 Hz, 1H), 7.92 (dt, J = 2.1, 0.8 Hz 1H), 7.43 (dd, J = 8.3, 7.6 Hz, 1H), 7.28 (dd, J = 8.3, 1.2 Hz, 1H), 7.13 (dd, J = 7.6, 1.2 Hz, 1H), 2.84 (qd, J = 7.6, 0.8 Hz, 2H), 1.35 (t, J = 7.6 Hz, 3H).

13C NMR (100 MHz, CDCl3): δ 152.4, 149.5, 137.7, 137.1, 133.8, 128.7, 127.9, 117.7, 109.4,

MP: 66 - 68 °C.

Note: Compound has an assigned CAS number (11470-98-5), but no published spectra or melting point were found.

Yield: 52% yield; 75.7 mg of 6a was isolated as a white solid.

^1H NMR (400 MHz, CDCl 3): δ 8.69 (d, J = 2.0 Hz, 1H), 7.91 (d, J = 2.0 Hz, 1H), 7.51 – 7.03 (m, 8H), 4.19 (s, 2H).

^13C NMR (100 MHz, CDCl 3): δ 152.4, 149.7, 139.8, 137.2, 135.2, 134.9, 129.1, 129.0, 128.6, 128.1, 126.8, 117.8, 109.8, 39.5.

HRMS (DART): calc. for C_{16}H_{14}NO [M+H]^+: 236.1070, found: 236.1075.

MP: 97 - 99 °C.

Note: Compound has an assigned CAS number (457948-80-0), but no published spectra were found for comparison.

Yield: 95% yield; 61.4 mg of 10a was isolated as a white solid.

^1H NMR (400 MHz, CDCl 3): δ 7.79 (s, 1H), 7.35 (dd, J = 8.2, 7.7 Hz, 1H), 7.20 (dd, J = 8.2, 1.2 Hz, 1H), 7.09 (dd, J = 7.7, 1.2 Hz, 1H), 2.94 (q, J = 7.4 Hz, 2H), 2.44 (s, 3H), 1.41 (t, J = 7.4 Hz, 3H).

^13C NMR (100 MHz, CDCl 3): δ 160.8, 151.9, 136.5, 135.6, 130.7, 127.4, 126.8, 117.0, 108.8, 28.8, 19.2, 12.0.

MP: 44 - 46 °C, lit. 46 - 47 °C. 6

Note: Compound has an assigned CAS number (88611-52-3), but no published spectra were found for comparison.

Method B Friedländer synthesis of 8-hydroxyquinolines (7a, 9a, 12a). To an 8 mL sealed microwave vial was added 2-amino-3-hydroxybenzaldehyde 20 (40.8 mg, 0.30 mmol) in water (4 mL) and malononitrile 33 (29 µL, 0.45 mmol). The resulting mixture was then heated at 130 °C in the microwave reactor for 15 minutes at 120 °C. After that time, the reaction was then allowed to cool and the contents were transferred to a separatory funnel containing a saturated aqueous solution of sodium bicarbonate. The solution was then extracted with ethyl acetate three times. The organic layers were combined, dried with anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude solid was purified via flash column chromatography eluting with 95:5 to 4:1 hexanes:ethyl acetate to afford quinoline 12a as a white solid (50.5 mg, 92%).  Note: Reaction times for complete conversion of starting material ranged from 10 to 45 minutes.
Yield: 90% yield; 31.0 mg of 7a was isolated as a white solid.
Note: We have previously reported a synthesis of this compound, without microwave assistance.¹

Yield: 77% yield; 35.8 mg of 9a was isolated as a clear oil.
Note: We have previously reported a synthesis of this compound, without microwave assistance.¹

Yield: 92% yield; 50.5 mg of 12a was isolated as a white solid.
¹H NMR (400 MHz, Methanol-d₄): δ 8.44 (s, 1H), 7.20 (dd, J = 8.1, 1.5 Hz, 1H), 7.14 (dd, J = 8.1, 7.4 Hz, 1H), 7.05 (dd, J = 7.4, 1.5 Hz, 1H).
¹³C NMR (100 MHz, Methanol-d₄): δ 156.3, 151.8, 146.1, 140.5, 124.8, 123.3, 119.7, 117.2, 115.1, 96.7.
MP: 206 - 208 °C, lit. 202 - 203 °C.²
Note: Compound has an assigned CAS number (90800-72-9), but no published spectra were found for comparison.

Method C Friedländer synthesis of ethyl 8-hydroxy-2-methylquinoline-3-carboxylate (8a). To an 8 mL sealed microwave vial was added 2-amino-3-hydroxybenzaldehyde 20 (28.5 mg, 0.21 mmol) and ethyl acetoacetate 34 (53 µL, 0.42 mmol) in ethanol (3 mL). The resulting mixture was then heated at 130 °C in the microwave reactor for 65 minutes. After that time, the reaction was then allowed to cool and the contents were then transferred to a separatory funnel containing a saturated aqueous solution of sodium bicarbonate. The solution was then extracted with ethyl acetate three times. The organic layers were combined, dried with anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude solid was purified via flash column chromatography eluting with 95:5 to 9:1 hexanes:ethyl acetate to give 8a as a white solid (36.4 mg, 78%).
Note: We have previously reported the synthesis of this compound, without microwave assistance.¹
Synthesis of ethyl 8-hydroxy-2,4-dimethylquinoline-3-carboxylate (11a). To 0.3 mL of water was added 1-(2-amino-3-hydroxyphenyl)ethan-1-one (136 mg 0.90 mmol), ethyl acetoacetate 34 (170 µl, 1.35 mmol) and dodecylphosphonic acid (22.5 mg, 0.1 mmol). The resulting mixture was then heated at 90 °C for 6 hours. After that time, the reaction was then allowed to cool and the contents were transferred to a separatory funnel containing a saturated aqueous solution of sodium bicarbonate. The solution was then extracted with dichloromethane three times. The organic layers were combined, dried with anhydrous sodium sulfate, filtered and concentrated \textit{in vacuo}. The crude solid was purified via flash column chromatography eluting with 95:5 to 4:1 hexanes:ethyl acetate to give 11a as an off-white solid (206 mg, 93%). \textbf{Note:} This protocol was adopted from a previously reported procedure.\textsuperscript{7} The microwave-mediated synthesis of this compound was carried out via Method C (8.4 mg, 38%).

\[ \text{H NMR (400 MHz, CDCl}_3\text{): } \delta 7.40 - 7.35 \text{ (m, 2H)}, 7.14 \text{ (m, 1H)}, 4.47 \text{ (q, } J = 7.2 \text{ Hz, 2H)}, 2.66 \text{ (s, 3H)}, 2.58 \text{ (s, 3H)}, 1.43 \text{ (t, } J = 7.2 \text{ Hz, 3H)}. \]

\[ \text{13C NMR (100 MHz, CDCl}_3\text{): } \delta 169.1, 152.4, 152.1, 142.2, 136.9, 128.7, 127.2, 126.1, 114.4, 110.6, 61.8, 23.6, 15.9, 14.4. \]

\[ \text{HRMS (DART): calc. for C}_{14}\text{H}_{16}\text{NO}_3 \text{ [M+H]}^+: 246.1125, \text{ found: 246.1125.} \]

\[ \text{MP: 31 - 33 °C.} \]

General procedure for 5,7-dibromo-8-hydroxyquinolines (1-11). 8-Hydroxyquinoline 7a (53.2 mg, 0.24 mmol) was dissolved in dichloromethane (8 mL) before \textit{N}-bromosuccinimide (89.5 mg, 0.50 mmol) was added and allowed to stir at room temperature for two hours until reaction was complete (monitored by TLC). At this time, the reaction was concentrated and adsorbed onto silica gel (via dissolving the crude reaction contents and silica gel in dichloromethane, then concentrating via rotavap) and purified via column chromatography using 80:20 hexanes:ethyl acetate to elute pure halogenated quinoline 7 (120.3 mg, 94%).

\[ \text{Note:} \text{ We have previously reported a synthesis of this compound.}^{1} \]
Yield: 22% yield; 10.4 mg of 2 was isolated as a white solid.

**1H NMR (400 MHz, CDCl₃):** δ 8.71 (br. s, 1H), 8.49 (d, J = 8.8 Hz, 1H), 8.16 – 8.11 (m, 2H), 8.02 (d, J = 8.8 Hz, 1H), 7.87 (s, 1H), 7.60 – 7.49 (m, 3H).

**13C NMR (100 MHz, CDCl₃):** δ 156.7, 149.8, 138.5, 137.8, 137.2, 133.5, 130.5, 129.3, 127.8, 125.7, 121.0, 110.3, 104.3.


**MP:** 148 - 150 °C.

Yield: 78% yield; 70.9 mg of 3 was isolated as a white solid.

**1H NMR (400 MHz, CDCl₃):** δ 8.77 (ddd, J = 4.8, 1.8, 1.1 Hz, 1H), 8.73 (d, J = 8.8 Hz, 1H), 8.66 (br. s, 1H), 8.54 (d, J = 8.8 Hz, 1H), 8.53 (ddd, J = 8.0, 1.1, 1.1 Hz, 1H), 7.91 (ddd, J = 8.0, 1.8 Hz, 1H), 7.90 (s, 1H), 7.42 (ddd, J = 7.7, 4.8, 1.1 Hz, 1H).

**13C NMR (100 MHz, CDCl₃):** δ 155.6, 154.6, 149.8, 149.7, 138.2, 137.3, 137.3, 134.1, 126.8, 125.0, 122.0, 121.2, 110.6, 104.3.


**MP:** 225 - 227 °C.

Yield: 62% yield; 27.2 mg of 4 was isolated as a white solid.

**1H NMR (400 MHz, CDCl₃):** δ 8.62 (d, J = 1.7 Hz, 1H), 8.16 (d, J = 1.7 Hz, 1H), 7.84 (s, 1H), 2.56 (s, 3H).

**13C NMR (100 MHz, CDCl₃):** δ 151.2, 149.8, 137.1, 134.9, 133.9, 133.3, 126.6, 109.7, 102.9, 19.2.

**HRMS (DART):** calc. for C₁₀H₈Br₂NO [M+H]+: 317.8947, found: 317.8943.

**MP:** 153 - 155 °C.

Yield: 31% yield; 12.9 mg of 5 was isolated as a white solid.

**1H NMR (400 MHz, CDCl₃):** δ 8.67 (d, J = 1.7 Hz, 1H), 8.19 (d, J = 1.7 Hz, 1H), 7.87 (s, 1H), 2.90 (q, J = 7.6 Hz, 2H), 1.39 (t, J = 7.6 Hz, 3H).

**13C NMR (100 MHz, CDCl₃):** δ 150.8, 149.8, 139.4, 137.4, 133.9, 133.8, 126.8, 110.0, 102.9, 26.7, 15.4.

**HRMS (DART):** calc. for C₁₁H₁₀Br₂NO [M+H]+: 331.9104, found: 331.9096.

**MP:** 117 - 119 °C.

Yield: 28% yield; 15.4 mg of 6 was isolated as a white solid.

**1H NMR (400 MHz, CDCl₃):** δ 8.65 (d, J = 2.0 Hz, 1H), 8.21 (d, J = 2.0 Hz, 1H), 7.88 (s, 1H), 7.34 (dd, J = 8.0, 6.6 Hz, 2H), 7.29 – 7.19 (m, 3H), 4.21 (s, 2H).

**13C NMR (100 MHz, CDCl₃):** δ 151.1, 149.8, 139.1, 137.4, 136.6, 135.1, 134.2, 129.1, 127.1, 126.7, 110.0, 103.3, 39.6.

**HRMS (DART):** calc. for C₁₆H₁₂Br₂NO [M+H]+: 393.9260, found: 393.9270.

**MP:** 176 - 178 °C.
Yield: 94% yield; 120.3 mg of 7 was isolated as a white solid.
Note: We have previously reported the synthesis of this compound.1

Yield: 90% yield; 232.7 mg of 8 was isolated as a white solid.
Note: We have previously reported the synthesis of this compound.1

Yield: 62% yield; 32.8 mg of 9 was isolated as an off-white solid.
Note: We have previously reported the synthesis of this compound.1

Yield: 90% yield; 69.4 mg of 10 was isolated as an off-white solid.

$^{1}H$ NMR (400 MHz, CDCl$_3$): δ 8.01 (d, $J = 1.0$ Hz, 1H), 7.74 (s, 1H), 2.96 (q, $J = 7.4$ Hz, 2H), 2.48 (d, $J = 1.0$ Hz, 3H), 1.39 (t, $J = 7.4$ Hz, 3H).

$^{13}C$ NMR (100 MHz, CDCl$_3$): δ 162.7, 149.3, 136.6, 135.3, 132.6, 132.4, 125.4, 109.3, 102.3, 28.6, 19.3, 11.9.

MP: 144 - 146 °C, lit. 150 °C.6
Note: Compound has an assigned CAS number (857758-48-6), but no published spectra were found.

Yield: 79% yield; 53.0 mg of 11 was isolated as an off-white solid.

$^{1}H$ NMR (400 MHz, CDCl$_3$): δ 7.90 (s, 1H), 4.48 (q, $J = 7.1$ Hz, 2H), 2.97 (s, 3H), 2.65 (s, 3H), 1.44 (t, $J = 7.1$ Hz, 3H).

$^{13}C$ NMR (100 MHz, CDCl$_3$): δ 168.9, 153.9, 149.6, 143.7, 138.2, 136.6, 131.7, 124.0, 107.4, 104.2, 62.3, 23.3, 21.3, 14.4.

HRMS (DART): calc. for C$_{14}$H$_{14}$Br$_{2}$NO$_{3}$ [M+H]$^+$: 403.9315, found: 403.9302.

MP: 97 - 99 °C.
Synthesis of 5,7-dibromo-8-hydroxy-2-methylquinoline-3-carboxylic acid (13). To a round-bottom flask containing quinoline 8 (61.8 mg, 0.16 mmol) was added 1N sodium hydroxide (20 mL). The reaction was left to stir for 17 hours at room temperature. Upon completion, the reaction mixture was transferred to a separatory funnel, neutralized with 1N hydrochloric acid, and then extracted with dichloromethane. The organic layers were combined, dried with anhydrous sodium sulfate, and then filtered. The solvent was removed in vacuo to afford 13 as a pure white solid (56.3 mg, >99%), which was used without further purification.

\[ \text{1H NMR (400 MHz, } d_6\text{-DMSO): } \delta 8.79 (s, 1H), 8.05 (s, 1H), 2.96 (s, 3H). \]
\[ \text{13C NMR (100 MHz, } d_6\text{-DMSO): } \delta 166.9, 158.1, 150.3, 138.7, 138.3, 133.2, 126.2, 124.3, 109.4, 107.3, 25.0. \]
\[ \text{HRMS (DART): calc. for C}_{11}H_8Br_2NO_3 [M+H]^+: 361.8845, \text{ found: 361.8831.} \]
\[ \text{MP: 247 - 249 °C.} \]

General procedure for the synthesis of 5,7-dibromo-8-hydroxy-2-methylquinoline-3-esters (14 - 16). To a stirring solution of 5,7-dibromo-8-hydroxy-2-methylquinoline-3-carboxylic acid 13 (65.0 mg, 0.18 mmol) and dicyclohexyl carbodiimide (44.6 mg, 0.22 mmol) in dichloromethane (4 mL) was added methanol (1 mL, 24.7 mmol). The reaction was then brought to reflux and allowed to react for 6 hours. Upon completion by TLC, the reaction contents were washed with water and partitioned between ethyl acetate and water in a separatory funnel. The organic contents were collected and dried with anhydrous sodium sulfate. The solvent was filtered and removed in vacuo. The resulting crude solid was purified via column chromatography using 99:1 to 1:1 hexanes:ethyl acetate to afford 14 as a white solid (15.5 mg, 23%).

\[ \text{Yield: 23% yield; 15.5 mg of } 14 \text{ was isolated as a white solid.} \]
\[ \text{1H NMR (400 MHz, CDCl}_3\text{: } \delta 8.92 (s, 1H), 7.86 (s, 1H), 4.01 (s, 3H), 3.00 (s, 3H).} \]
\[ \text{13C NMR (100 MHz, CDCl}_3\text{: } \delta 166.3, 159.0, 149.2, 139.9, 138.6, 133.9, 125.7, 124.5, 110.8, 106.3, 53.0, 25.4.} \]
\[ \text{HRMS (DART): calc. for C}_{12}H_{10}Br_2NO_3 [M+H]^+: 375.9002, \text{ found: 375.9005.} \]
\[ \text{MP: 158 - 160 °C.} \]
Yield: 16% yield; 14.9 mg of 15 was isolated as a white solid.

\( ^1H \text{ NMR (400 MHz, CDCl}_3 \): } \delta 8.98 (s, 1H), 7.87 (s, 1H), 7.55 – 7.47 (m, 2H), 7.47 – 7.34 (m, 3H), 5.45 (s, 2H), 2.99 (s, 3H).

\( ^13C \text{ NMR (100 MHz, CDCl}_3 \): } \delta 165.8, 159.0, 149.2, 140.0, 138.6, 135.6, 134.0, 129.0, 128.8, 128.6, 125.8, 124.5, 110.9, 106.4, 67.8, 25.5.

HRMS (DART): calc. for C\(_{18}H_{14}Br_2NO_3\) [M+H]\(^+\): 451.9316, found: 451.9326.

MP: 105 - 107 °C.

Yield: 37% yield; 38.2 mg of 16 was isolated as a white solid.

\( ^1H \text{ NMR (400 MHz, CDCl}_3 \): } \delta 8.22 (s, 1H), 7.86 (s, 1H), 3.89 (m, 1H), 3.49 (dt, \( J = 10.7, 8.3 \text{ Hz} \), 1H), 2.78 (s, 3H), 2.07 – 1.94 (m, 2H), 1.93 – 1.85 (m, 2H), 1.84 – 1.76 (m, 2H), 1.75 – 1.66 (m, 2H), 1.64 – 1.49 (m, 4H), 1.31 – 1.19 (m, 2H), 1.19 – 0.97 (m, 6H).

\( ^13C \text{ NMR (100 MHz, CDCl}_3 \): } \delta 169.7, 155.7, 153.1, 149.3, 137.7, 134.0, 132.6, 132.8, 124.1, 110.1, 105.2, 58.2, 50.0, 32.7, 31.1, 26.3, 25.5, 25.3, 24.7, 23.1.

HRMS (DART): calc. for C\(_{24}H_{30}Br_2N_3O_3\) [M+H]\(^+\): 568.0630, found: 568.0632.

MP: 96 - 98 °C.

Note: This compound was isolated as a side product obtained during the synthesis of halogenated quinoline 14.

---

**General procedure for the synthesis of 5,7-dibromo-8-hydroxy-2-methylquinoline-3-amides (17 - 19).** To a solution of 5,7-dibromo-8-hydroxy-2-methylquinoline-3-carboxylic acid 13 (59.1 mg, 0.16 mmol) and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (37.7 mg, 0.20 mmol) in acetone (6 mL) was added benzylamine (18 µL, 0.16 mmol). The reaction was then brought to reflux and allowed to react for 5 hours. Upon completion by TLC, the reaction contents were washed with water and partitioned between ethyl acetate and water in a separatory funnel. The organic contents were collected and dried with anhydrous sodium sulfate. The solvent was filtered and removed in vacuo. The resulting crude solid was purified via column chromatography using 95:5 to 1:1 hexanes:ethyl acetate to afford the product, 18, as a white solid (21.1 mg, 29%).

Yield: 26% yield; 14.8 mg of 17 was isolated as a white solid.

\( ^1H \text{ NMR (400 MHz, CDCl}_3 \): } \delta 8.20 (s, 1H), 7.78 (s, 1H), 6.35 (br. s, 1H), 3.48 (q, \( J = 6.7 \text{ Hz} \), 2H), 2.79 (s, 3H), 1.72 (qt, \( J = 7.3, 7.3 \text{ Hz} \), 2H), 1.05 (t, \( J = 7.3 \text{ Hz} \), 3H).

\( ^13C \text{ NMR (100 MHz, CDCl}_3 \): } \delta 167.9, 156.9, 148.9, 137.5, 134.1, 133.7, 132.6, 124.1, 110.2, 105.0, 42.2, 23.4, 23.1, 11.7.

HRMS (DART): calc. for C\(_{14}H_{15}Br_2N_2O_2\) [M+H]\(^+\): 402.9475, found: 402.9479.

MP: 184 - 186 °C.
**Yield:** 29% yield; 21.1 mg of 18 was isolated as a white solid.

**1H NMR (400 MHz, CDCl₃):** \(\delta 8.30 \text{ (s, 1H)}, 7.82 \text{ (s, 1H)}, 7.43 \text{ – 7.37 (m, 4H)}, 7.34 \text{ (m, 1H)}, 6.44 \text{ (m, 1H)}, 4.69 \text{ (s, 2H)}, 2.83 \text{ (s, 3H)}.\)

**13C NMR (100 MHz, CDCl₃):** \(\delta 167.6, 156.9, 149.1, 137.8, 137.7, 134.3, 133.8, 132.1, 132.1, 129.2, 128.2, 128.2, 124.2, 110.2, 105.3, 44.6, 44.4, 23.6.\)


**MP:** 208 - 210 °C.

**Note:** Observed additional ¹³C NMR peaks which likely correspond to amide rotamers. This was also observed in \(d_6\)DMSO. No impurities were observed via ¹H NMR or HRMS.

**Yield:** 15% yield; 18.4 mg of 19 was isolated as a white solid.

**1H NMR (400 MHz, CDCl₃):** \(\delta 8.22 \text{ (s, 1H)}, 7.87 \text{ (s, 1H)}, 3.90 \text{ (m, 2H)}, 3.84 \text{ (m, 2H)}, 3.64 \text{ (m, 2H)}, 3.29 \text{ (m, 2H)}, 2.75 \text{ (s, 3H)}.\)

**13C NMR (100 MHz, CDCl₃):** \(\delta 167.5, 155.4, 149.3, 137.8, 134.0, 133.9, 131.5, 124.6, 110.2, 105.1, 67.0, 67.0, 47.7, 42.5, 22.9.\)


**MP:** 186 - 188 °C.

---

**General procedure for the synthesis of 8-hydroxyquinolines under acidic conditions and traditional oil bath heating.** To a stirring solution of 2-amino-3-hydroxybenzaldehyde 20 (74.0 mg, 0.54 mmol) in toluene (27 mL) was added propionaldehyde 29 (46 µL, 0.65 mmol) and \(p\)-toluenesulfonic acid (5.4 mg, 0.03 mmol). The resulting mixture was then heated to reflux for 24 hours using a Dean-Stark trap. After that time, the reaction was then allowed to cool and the mixture was washing with saturated sodium bicarbonate. The solution was then extracted with ethyl acetate, which was then dried with anhydrous sodium sulfate, filtered, and removed in vacuo. The crude solid was purified via flash column chromatography eluting with 95:5 to 4:1 hexanes:ethyl acetate to afford quinoline 4a as a white solid (9.2 mg, 11%). **Note:** This protocol was modified from a previously published procedure.⁸

---

**General procedure for the synthesis of 8-hydroxyquinolines under basic conditions and traditional oil bath heating.** To a stirring solution of 2-amino-3-hydroxybenzaldehyde 20 (128.0 mg, 0.93 mmol) in ethanol (10 mL) was added potassium hydroxide (141 mg, 2.52 mmol) and 3-pentanone 25 (148 µL, 1.40 mmol). The resulting mixture was then heated to reflux for 24 hours. After that time, the reaction was then allowed to cool...
and the solvent was removed in vacuo. The crude residue was taken up in dichloromethane, transferred to a separatory funnel and then neutralized with 2N hydrochloric acid. The solution was then extracted with dichloromethane three times. The organic layers were combined, dried with anhydrous sodium sulfate, filtered and concentrated in vacuo. The crude solid was purified via flash column chromatography eluting with 95:5 to 4:1 hexanes:ethyl acetate to afford quinoline 10a as a white solid (42.0 mg, 24%). Note: All reaction yields for traditional oil bath conversion are listed in the manuscript.
3.) Biological Methods:

A.) Minimum Inhibitory Concentration (MIC) Susceptibility Assay (in 96-well plate):

The minimum inhibitory concentration (MIC) for each quinoline was determined by the broth microdilution method as recommended by the Clinical and Laboratory Standards Institute (CLSI). In a 96-well plate, eleven two-fold serial dilutions of each compound were made in a final volume of 100 μL Luria Broth. Each well was inoculated with ~10^5 bacterial cells at the initial time of incubation, prepared from a fresh log phase culture (OD_{600} of 0.5 to 1.0 depending on bacterial strain). The MIC was defined as the lowest concentration of compound that prevented bacterial growth after incubating 16 to 18 hours at 37 °C (MIC values were supported by spectrophotometric readings at OD_{600}). The concentration range tested for each quinoline/antibacterial during this study was 0.10 to 100 μM. DMSO served as our vehicle and negative control in each microdilution MIC assay. DMSO was serially diluted with a top concentration of 1% v/v. Each experiment was conducted in three replicates from separate, individual bacterial colonies.

B.) Calgary Biofilm Device (CBD) Experiments

Minimum Bactericidal Concentrations (MBC) and Minimum Biofilm Eradication Concentrations (MBEC)

Biofilm eradication experiments were performed using the Calgary Biofilm Device to determine MBC/MBEC values for various compounds of interest (Innovotech, product code: 19111). The Calgary device (96-well plate with lid containing pegs to establish biofilms on) was inoculated with 125 μL of a mid-log phase culture diluted 1,000-fold in tryptic soy broth with 0.5% glucose (TSBG) to establish bacterial biofilms after incubation at 37 °C for 24 hours. The lid of the Calgary device was then removed, washed and transferred to another 96-well plate containing 2-fold serial dilutions of the test compounds (the “challenge plate”). The total volume of media with compound in each well in the challenge plate is 150 μL. The Calgary device was then incubated at 37 °C for 24 hours. The lid was then removed from the challenge plate and MBC/MBEC values were determined using different final assays. To determine MBC values, 20 μL of the challenge plate was transferred into a fresh 96-well plate containing 180 μL TSBG and incubated overnight at 37 °C. The MBC values were determined as the concentration giving a lack of visible bacterial growth (i.e., turbidity). For determination of MBEC values, the Calgary device lid (with attached pegs/treated biofilms) was transferred to a new 96-well plate containing 150 μL of fresh TSBG media in each well and incubated for 24 hours at 37 °C to allow viable biofilms to grow and disperse resulting in turbidity after the incubation period. MBEC values were determined as the lowest test concentration that resulted in eradicated biofilm (i.e., wells that had no turbidity after final incubation). Each experiment was conducted in three replicates from separate, individual bacterial colonies.

Supporting Table 1 MBC/MBEC for select HQs against MRSA BAA 1707 and BAA 44.

<table>
<thead>
<tr>
<th>Compound</th>
<th>MRSA BAA 1707 MBC / MBEC</th>
<th>MRSA BAA 44 MBC / MBEC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>31.3 ^/ 31.3 ^</td>
<td>46.9 ^/ 93.8 ^</td>
</tr>
<tr>
<td>4</td>
<td>46.9 ^/ 1000 ^</td>
<td>93.8 ^/ &gt; 2000</td>
</tr>
<tr>
<td>5</td>
<td>62.5 / 250</td>
<td>125 / &gt; 1000</td>
</tr>
<tr>
<td>7</td>
<td>&gt; 1000 / &gt; 1000</td>
<td>&gt; 1000 / &gt; 1000</td>
</tr>
<tr>
<td>8</td>
<td>500 ^/ &gt; 1000</td>
<td>&gt; 1000 / &gt; 1000</td>
</tr>
<tr>
<td>9</td>
<td>7.8 / 3.9</td>
<td>23.5 ^/ 15.6</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>5.9 ^/ &gt; 2000</td>
<td>3.0 ^/ &gt; 2000</td>
</tr>
</tbody>
</table>

Note: *Midpoint value of a two-fold range. All concentrations have been recorded in μM.
F.) Haemolysis Assay:

We performed haemolysis assays based on a previous procedure.\(^5\) Freshly drawn human red blood cells (hRBC with ethylenediaminetetraacetic acid (EDTA) as an anticoagulant) were washed with Tris-buffered saline (0.01M Tris-base, 0.155 M sodium chloride (NaCl), pH 7.2) and centrifuged for 5 minutes at 3,500 rpm. The washing was repeated three times with the buffer. In 96-well plate, test compounds were added to the buffer from DMSO stocks. Then 2% hRBCs (50 µL) in buffer were added to test compounds to give a final concentration of 200 µM. The plate was then incubated for 1 hour at 37 °C. After incubation, the plate was centrifuged for 5 minutes at 3,500 rpm. Then 80 µL of the supernatant was transferred to another 96-well plate and the optical density (OD) was read at 405 nm. DMSO served as our negative control (0% haemolysis) while Triton X served as our positive control (100% haemolysis). The percent of haemolysis was calculated as \((\text{OD}_{405} \text{ of the compound} - \text{OD}_{405} \text{ DMSO}) / (\text{OD}_{405} \text{ Triton X} - \text{OD}_{405} \text{ buffer})\). Each experiment was conducted in three replicates.
4.) Literature References:


**S. epidermidis (MRSE 35984) Biofilm Eradication (CBD Assay)**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>MBC (µM)</th>
<th>MBEC (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A) DMSO</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>B) 1 *</td>
<td>7.8</td>
<td>2</td>
</tr>
<tr>
<td>C) 8 *</td>
<td>62.5</td>
<td>15.6</td>
</tr>
<tr>
<td>D) 9 *</td>
<td>3.9</td>
<td>1</td>
</tr>
<tr>
<td>E) 5 *</td>
<td>62.5</td>
<td>31.3</td>
</tr>
<tr>
<td>F) 15 *</td>
<td>31.3</td>
<td>31.3</td>
</tr>
<tr>
<td>G) 4 **</td>
<td>15.6</td>
<td>7.8</td>
</tr>
</tbody>
</table>

**E. faecium (VRE 700221) Biofilm Eradication (CBD Assay)**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>MBC (µM)</th>
<th>MBEC (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A) DMSO</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>B) 1 **</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>C) 8 **</td>
<td>3.9</td>
<td>15.6</td>
</tr>
<tr>
<td>D) 9 **</td>
<td>62.5</td>
<td>15.6</td>
</tr>
<tr>
<td>E) 5 **</td>
<td>31.3</td>
<td>15.6</td>
</tr>
<tr>
<td>F) 15 **</td>
<td>7.8</td>
<td>15.6</td>
</tr>
<tr>
<td>G) 4 ***</td>
<td>7.8</td>
<td>7.8</td>
</tr>
<tr>
<td>H) Vancomycin *</td>
<td>&gt;200</td>
<td>&gt;200</td>
</tr>
</tbody>
</table>
**MRSA-2 Biofilm Eradication (CBD Assay)**

- **A)** DMSO
- **B)** 1 *
- **C)** 8 *
- **D)** 9 *
- **E)** 4 **
- **F)** 5 *
- **G)** 15 *
- **H)** Vancomycin **

**MRSA Planktonic (MBC)**

- **MBC (µM)**
  - 15.6
  - 31.3
  - 7.8
  - 15.6
  - 31.3
  - 250
  - 2

**MRSA Biofilms (MBEC)**

- **MBEC (µM)**
  - --
  - 31.3
  - 31.3
  - 31.3
  - 62.5
  - 125
  - >1000
  - >2000

---

**MRSA BAA 44 Biofilm Eradication (CBD Assay)**

- **A)** DMSO
- **B)** 1 *
- **C)** 9 *
- **D)** Vancomycin **
- **E)** 8 *
- **F)** 7 *
- **G)** 5 *
- **H)** 4 **

**MRSA BAA 44 Planktonic (MBC)**

- **MBC (µM)**
  - 62.5
  - 15.6
  - 3.9
  - >1000
  - >1000
  - 125
  - 125

**MRSA BAA 44 Biofilms (MBEC)**

- **MBEC (µM)**
  - --
  - 125
  - 15.6
  - >2000
  - >1000
  - >1000
  - >1000
  - >2000
### MRSA BAA 1707 Biofilm Eradication (CBD Assay)

#### MRSA BAA 1707 Planktonic (MBC)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>MBC (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A) DMSO</td>
<td>--</td>
</tr>
<tr>
<td>B) 1 *</td>
<td>31.3</td>
</tr>
<tr>
<td>C) 9 *</td>
<td>7.8</td>
</tr>
<tr>
<td>D) Vancomycin **</td>
<td>3.9</td>
</tr>
<tr>
<td>E) 8 *</td>
<td>500</td>
</tr>
<tr>
<td>F) 7 *</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>G) 5 *</td>
<td>62.5</td>
</tr>
<tr>
<td>H) 4 **</td>
<td>31.3</td>
</tr>
</tbody>
</table>

#### MRSA BAA 1707 Biofilms (MBEC)

<table>
<thead>
<tr>
<th>MBEC (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>--</td>
</tr>
<tr>
<td>31.3</td>
</tr>
<tr>
<td>3.9</td>
</tr>
<tr>
<td>&gt;2000</td>
</tr>
<tr>
<td>1000</td>
</tr>
<tr>
<td>&gt;1000</td>
</tr>
<tr>
<td>250</td>
</tr>
<tr>
<td>2000</td>
</tr>
</tbody>
</table>

---

### MRSA BAA 1707 Biofilm Eradication (CBD Assay)

#### MRSA BAA 1707 Planktonic (MBC)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>MBC (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A) DMSO</td>
<td>--</td>
</tr>
<tr>
<td>B) 1 *</td>
<td>62.5</td>
</tr>
<tr>
<td>C) 8 *</td>
<td>500</td>
</tr>
<tr>
<td>D) 15 *</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>E) 18 **</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>F) 10 *</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>G) QAC-10 **</td>
<td>&gt;1000</td>
</tr>
<tr>
<td>H) Vancomycin *</td>
<td>125</td>
</tr>
</tbody>
</table>

#### MRSA BAA 1707 Biofilms (MBEC)

<table>
<thead>
<tr>
<th>MBEC (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>--</td>
</tr>
<tr>
<td>125</td>
</tr>
<tr>
<td>&gt;1000</td>
</tr>
<tr>
<td>&gt;1000</td>
</tr>
<tr>
<td>&gt;1000</td>
</tr>
<tr>
<td>&gt;1000</td>
</tr>
<tr>
<td>62.5</td>
</tr>
<tr>
<td>&gt;1000</td>
</tr>
</tbody>
</table>
### S. epidermidis (MRSE 35984) MIC

<table>
<thead>
<tr>
<th></th>
<th>MIC (µM)</th>
<th></th>
<th>MIC (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A) DMSO</td>
<td>--</td>
<td>A) DMSO</td>
<td>--</td>
</tr>
<tr>
<td>B) 1</td>
<td>0.2</td>
<td>B) 2</td>
<td>0.39</td>
</tr>
<tr>
<td>C) 8</td>
<td>0.1</td>
<td>C) 3</td>
<td>3.13</td>
</tr>
<tr>
<td>D) 13</td>
<td>25</td>
<td>D) 10</td>
<td>0.1</td>
</tr>
<tr>
<td>E) 7</td>
<td>6.25</td>
<td>E) 4</td>
<td>0.78</td>
</tr>
<tr>
<td>F) 6</td>
<td>3.13</td>
<td>F) 14</td>
<td>0.2</td>
</tr>
<tr>
<td>G) 17</td>
<td>12.5</td>
<td>G) 18</td>
<td>6.25</td>
</tr>
<tr>
<td>H) 11</td>
<td></td>
<td>G) 18</td>
<td>0.78</td>
</tr>
</tbody>
</table>

### E. faecium (VRE 700221) MIC

<table>
<thead>
<tr>
<th></th>
<th>MIC (µM)</th>
<th></th>
<th>MIC (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A) DMSO</td>
<td>--</td>
<td>A) DMSO</td>
<td>--</td>
</tr>
<tr>
<td>B) 1</td>
<td>1.56</td>
<td>B) 2</td>
<td>0.78</td>
</tr>
<tr>
<td>C) 8</td>
<td>0.78</td>
<td>C) 3</td>
<td>50</td>
</tr>
<tr>
<td>D) 17</td>
<td>0.78</td>
<td>D) 10</td>
<td>0.78</td>
</tr>
<tr>
<td>E) 10</td>
<td>3.13</td>
<td>E) 4</td>
<td>3.13</td>
</tr>
<tr>
<td>F) 4</td>
<td>3.13</td>
<td>F) 14</td>
<td>3.13</td>
</tr>
<tr>
<td>G) 14</td>
<td>25</td>
<td>G) 18</td>
<td>25</td>
</tr>
<tr>
<td>H) 18</td>
<td></td>
<td>G) 18</td>
<td>25</td>
</tr>
</tbody>
</table>